BRPI0510367A - métodos e composições para o tratamento de doenças policìsticas - Google Patents

métodos e composições para o tratamento de doenças policìsticas

Info

Publication number
BRPI0510367A
BRPI0510367A BRPI0510367-3A BRPI0510367A BRPI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A BR PI0510367 A BRPI0510367 A BR PI0510367A
Authority
BR
Brazil
Prior art keywords
methods
compositions
gene
treatment
diseases
Prior art date
Application number
BRPI0510367-3A
Other languages
English (en)
Inventor
Oxana Beskrovnaya
Herve Husson
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0510367A publication Critical patent/BRPI0510367A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE DOENçAS POLICìSTICAS. A presente invenção refere-se a composições e métodos para diagnosticar e tratar distúrbios policísticos através da inibição da atividade biológica de um gene agora relacionado com o aparecimento desse distúrbio. Somente a título de ilustração, o gene do Fator de Crescimento do Tecido Conectivo (CTGF) é um exemplo de tal gene. Também são providos por esta invenção composições e métodos para tratar ou aliviar lesões císticas anormais e doenças associadas com a formação de cistos no tecido. Os métodos e as composições tratam e aliviam a formação patológica de cistos nos tecidos através da inibição ou do aumento da expressão do gene, ou da atividade biológica do seu produto da sua expressão do gene ou do seu receptor.
BRPI0510367-3A 2004-04-29 2005-04-29 métodos e composições para o tratamento de doenças policìsticas BRPI0510367A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56667004P 2004-04-29 2004-04-29
US59038504P 2004-07-22 2004-07-22
PCT/US2005/014982 WO2005117941A2 (en) 2004-04-29 2005-04-29 Methods and compositions for the treatment of polycystic diseases

Publications (1)

Publication Number Publication Date
BRPI0510367A true BRPI0510367A (pt) 2007-11-06

Family

ID=35463346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510367-3A BRPI0510367A (pt) 2004-04-29 2005-04-29 métodos e composições para o tratamento de doenças policìsticas

Country Status (6)

Country Link
EP (1) EP1740221A4 (pt)
JP (1) JP2007535562A (pt)
BR (1) BRPI0510367A (pt)
CA (1) CA2564092A1 (pt)
MX (1) MXPA06012446A (pt)
WO (1) WO2005117941A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
EP1808694A1 (en) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
EP2617423A1 (en) * 2006-10-19 2013-07-24 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
JP5995207B2 (ja) * 2014-11-28 2016-09-21 学校法人 学習院 含ホウ素ポルフィリン誘導体
KR102288447B1 (ko) * 2018-12-28 2021-08-10 서울대학교산학협력단 Ctgf 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
AU1682699A (en) * 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression

Also Published As

Publication number Publication date
WO2005117941A3 (en) 2006-05-18
MXPA06012446A (es) 2007-01-17
JP2007535562A (ja) 2007-12-06
EP1740221A4 (en) 2009-01-07
EP1740221A2 (en) 2007-01-10
CA2564092A1 (en) 2005-12-15
WO2005117941A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
Mendes et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease
Zhang et al. Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
Muneer et al. Endoplasmic reticulum stress: implications for neuropsychiatric disorders
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2007024535A3 (en) Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2009011871A3 (en) Thiadiazole modulators of pkb
He et al. Gene expression signatures in tree shrew choroid in response to three myopiagenic conditions
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0510367A (pt) métodos e composições para o tratamento de doenças policìsticas
Lu et al. Isoquercetin ameliorates tunicamycin-induced apoptosis in rat dorsal root ganglion neurons via suppressing ROS-dependent endoplasmic reticulum stress
Irnaten et al. Transient receptor potential channels TRPC1/TRPC6 regulate lamina cribrosa cell extracellular matrix gene transcription and proliferation
WO2023091644A3 (en) Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto
WO2010030936A3 (en) Novel autophagy regulators atg14l and rubicon
Xu et al. Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons
MX2026002733A (es) Composiciones de oligonucleotidos de cadena doble relacionadas con la subunidad beta e de la inhibina y metodos relacionados con estas
Baek et al. Insulin withdrawal-induced cell death in adult hippocampal neural stem cells as a model of autophagic cell death
Wu et al. PKC isozymes in the enhanced regrowth of retinal neurites after optic nerve injury
BRPI0512496A (pt) processos e composições para o tratamento de doenças policìsticas
WO2007046087A3 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin disesaes, disorders or conditions
Ni et al. Long-term effects of recurrent neonatal seizures on neurobehavioral function and related gene expression and its intervention by inhibitor of cathepsin B
Wang et al. Lycopene can modulate the LRP1 and RAGE transporters expression at the choroid plexus in Alzheimer’s disease rat
Li et al. Valproic acid protects neurons and promotes neuronal regeneration after brachial plexus avulsion
WO2003073983A3 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
WO2003030836A3 (en) Neuronal regeneration

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.